Which biotech company does Vertex admire? Hint: It’s one some analysts think the cystic fibrosis drugmaker should have snapped up a long time ago. The “analogy that we’ve often talked about is with ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, Vertex's revenue soared 11% to more than $3 billion -- that's with net ...

Biotech stocks can generate eye-catching returns on capital in a few short years. For example, Vertex Pharmaceuticals (NASDAQ: VRTX) and Galapagos N.V. (NASDAQ: GLPG) have both made early investors ...

According to data fromS&P Global Market Intelligence, shares of the rare disease specialistVertex Pharmaceuticals (NASDAQ: VRTX) rose by 16.6% last month. The drugmaker's shares appear to have ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report. Net income of $3.05 a share ...

Biotech stocks can generate eye-catching returns on capital in a few short years. For example, Vertex Pharmaceuticals (VRTX +0.60%) and Galapagos N.V. (GLPG 0.64%) have both made early investors ...